Elsevier

Urology

Volume 39, Issue 6, June 1992, Pages 577-582
Urology

Experience with weekly doxorubicin (adriamycin) in hormone-refractory stage D2 prostate cancer

https://doi.org/10.1016/0090-4295(92)90023-PGet rights and content

Abstract

One hundred eleven patients with endocrine-refractory Stage D prostate cancer were treated with weekly administration of 20 mg/m2 body surface area of doxorubicin hydrochloride (Adriamycin). Fifty-seven were part of a randomized study comparing doxorubicin and prednisone to prednisone alone. There were significantly more subjective responders in the doxorubicin group than in the prednisone group (p < 0.01). The number of patients with evidence of stable disease was also higher during the chemotherapy arm compared with prednisone alone (p = 0.02). Patients taking doxorubicin had a slightly longer period of stable disease than did those taking prednisone (p = 0.08). Overall survival, however, was not prolonged (p = 0.26). Fifty-four patients took part in an open trial and 69 percent responded to treatment. All of these had clinical improvement. Side effects were minimal with cardiotoxicity noted in less than 15 percent among patients with side effects. Over 35 percent had no side effects. Thus single agent, weekly doxorubicin therapy as evaluated in our experience, while well tolerated and of subjective benefit, does not provide the patient with a significant longer progression free survival or improved overall survival.

References (15)

There are more references available in the full text version of this article.

Cited by (35)

  • A new jasmonic acid stereoisomeric derivative induces apoptosis via reactive oxygen species in human prostate cancer cells

    2012, Cancer Letters
    Citation Excerpt :

    However, in advanced stages of prostate cancer, growth and development typically become refractory to androgen effects and cells continue to grow unchecked [3]. Aggressive treatment of patients with combination chemotherapy usually results in severe side-effects and is rarely curative [4–6]. In fact, androgen-independent tumors also become resistant to a wide variety of cytotoxic drugs.

  • Effect of vicanicin and protolichesterinic acid on human prostate cancer cells: Role of Hsp70 protein

    2012, Chemico-Biological Interactions
    Citation Excerpt :

    However, in advanced stages of prostate cancer, growth and development typically become refractory to androgen effects and cells continue to grow unchecked [24]. Aggressive treatment of patients with combination chemotherapy usually results in severe side-effects and is rarely curative [25–27]. In fact, androgen-independent tumors also become resistant to a wide variety of cytotoxic drugs.

  • The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer

    2008, Cancer Treatment Reviews
    Citation Excerpt :

    A phase II study reported substantial palliative effect and acceptable toxicity with weekly Epi combined with medroxyprogesterone acetate (MPA), while a randomized trial described that heart failure was frequently observed in patients receiving this combination regimen.57,58 No significant difference in overall survival was found between patients who received weekly Dox 20 plus prednisone (P) or P alone.28 Since a significant synergistic antitumour effect had been demonstrated in vitro in testosterone-sensitive human prostate carcinoma cell line LNCaP with the combination of Epi and the polysulfonated naphtylurea suramin (S), some investigators tested this combination in HRPC patients.59

  • Biweekly Doxorubicin/Ketoconazole as Second-Line Treatment in Docetaxel-Resistant, Hormone-Refractory Prostate Cancer

    2008, Urology
    Citation Excerpt :

    We observed only 1 case of Grade 2 cardiac toxicity. This low incidence of cardiotoxicity should be mainly attributed to the low median total dose of doxorubicin and is consistent with a previous report of a weekly administration of doxorubicin at 20 mg/m2.8 The high occurrence of nail changes is worth discussing.

View all citing articles on Scopus
View full text